Nuveen LLC Purchases New Stake in Standard BioTools Inc. $LAB

Nuveen LLC purchased a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 798,482 shares of the company’s stock, valued at approximately $862,000. Nuveen LLC owned approximately 0.21% of Standard BioTools at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LAB. Pacific Capital Partners Ltd bought a new position in shares of Standard BioTools in the 1st quarter worth about $1,701,000. Royce & Associates LP lifted its position in shares of Standard BioTools by 37.4% in the 1st quarter. Royce & Associates LP now owns 2,000,503 shares of the company’s stock worth $2,161,000 after buying an additional 545,000 shares during the last quarter. GSA Capital Partners LLP lifted its position in shares of Standard BioTools by 369.2% in the 1st quarter. GSA Capital Partners LLP now owns 608,656 shares of the company’s stock worth $657,000 after buying an additional 478,922 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Standard BioTools by 80.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 554,203 shares of the company’s stock worth $970,000 after buying an additional 247,332 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Standard BioTools by 9.3% in the 4th quarter. Northern Trust Corp now owns 2,875,160 shares of the company’s stock worth $5,032,000 after buying an additional 243,522 shares during the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Casdin Partners Master Fund, L purchased 200,000 shares of the stock in a transaction on Monday, August 25th. The shares were bought at an average price of $1.24 per share, for a total transaction of $248,000.00. Following the completion of the acquisition, the director directly owned 60,150,000 shares in the company, valued at approximately $74,586,000. This trade represents a 0.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 883,220 shares of company stock worth $1,099,946 in the last 90 days. Company insiders own 23.16% of the company’s stock.

Standard BioTools Stock Performance

Shares of LAB opened at $1.24 on Wednesday. The firm has a market cap of $473.67 million, a PE ratio of -3.88 and a beta of 1.29. The firm’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.18. Standard BioTools Inc. has a twelve month low of $0.92 and a twelve month high of $2.32.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LAB shares. TD Cowen downgraded shares of Standard BioTools from a “buy” rating to a “hold” rating and set a $1.55 price target on the stock. in a research report on Wednesday, August 13th. Wall Street Zen upgraded shares of Standard BioTools from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Cowen cut shares of Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $1.55.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.